Across TCGA pan-cancer cohorts, DNAJB9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DNAJB9 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DNAJB9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJB9 expression acts as an unfavorable survival marker.
HNSC, LUSC, and UCEC are the cancer types where DNAJB9 Mutation most reproducibly stratifies survival.